Shanghai Anruite Biomedical Technology

Shanghai Anruite Biomedical Technology is a clinical-stage biotechnology company specializing in the development and large-scale production of recombinant human albumin (rHA). Utilizing a proprietary yeast-based expression system (Pichia pastoris), the company provides a safe, pathogen-free, and sustainable alternative to plasma-derived albumin, addressing chronic global shortages. Its lead therapeutic candidate is currently in Phase 3 clinical trials for indications including hypoalbuminemia and liver cirrhosis with ascites. Beyond therapeutics, Anruite provides high-purity recombinant albumin for use as a pharmaceutical excipient and in cell culture media. The company operates integrated R&D and manufacturing facilities to support its mission of advancing recombinant blood substitutes.